EUROPEAN COMMISSION

Brussels, 22.9.2026
C(2026) 6848 final

PUBLIC VERSION

EQT Fund Management S.à r.l.
51A, Boulevard Royal
2449 Luxembourg
Luxembourg

Subject: **Case M.12554 - EQT FUNDS / CORZA BIOSURGERY BUSINESS**
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004 ([1]) and Article 57 of the Agreement on the European Economic Area ([2])

Dear Sir or Madam,

(1) On 31 August 2026, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation following a referral pursuant to Article 4(5) of the Merger Regulation, by which EQT Fund Management S.à r.l. ("EFMS", Luxembourg), controlled by EQT AB ("EQT", Sweden), will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control over the whole of the Corza Medical's biosurgery business unit (the "Target Group"), which consists of several companies incorporated in Europe and the United States, by way of purchase of shares. ([3])

(2) The business activities of the undertakings concerned are the following:

– EFMS is the alternative investment fund manager of EQT X, a private investment fund which is part of the EQT group of investment funds. The portfolio companies of the EQT group are active in a variety of industries and across various geographies,

– The Target Group's business is the manufacturing and selling of Tachosil, a fibrin sealant patch used during surgical procedures to achieve haemostasis and seal tissue surfaces (including the cut surfaces of internal organs), to provide suture support in vascular surgery where conventional

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.
([2]) OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').
([3]) OJ C, C/2026/4763, 9.9.2026

surgical techniques are insufficient, and, in neurological surgery, to seal the dura mater and prevent postoperative cerebrospinal fluid leakage.

(3) After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5 (c) of the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004. ([4])

(4) For the reasons set out in the Notice on a simplified treatment, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed)
Anthony WHELAN
Director-General
Directorate-General for Competition

([4]) OJ C 160, 5.5.2023, p. 1 (the 'Notice on a simplified treatment').